Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]-dimethyldiphenylammonium trifluoromethanesulfonate
- Development stage
- Preclinical
- Lead developer
- Technion-Israel Institute of Technology
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**[11C]-DMDPA** is a radiolabeled quaternary ammonium salt, specifically [11C]-dimethyldiphenylammonium trifluoromethanesulfonate, developed as a novel positron emission tomography (PET) myocardial perfusion imaging (MPI) agent. It displays rapid, high, and sustained cardiac uptake as well as favorable distribution kinetics relative to blood and adjacent non-target organs in preclinical animal models. Its metabolic stability and imaging properties compare favorably to clinically used PET-MPI probes. The mechanism of cardiac uptake is hypothesized to be related to the compound’s cationic nature, analogous to technetium and other ammonium salt-based perfusion agents, but the precise molecular target for myocardial uptake is not fully elucidated[1][4].
- Other names
- [11C]-DMDPA[11C]DMDPA[(11)C]DMDPA(11C)Dmdpa[11C]-dimethyl-diphenylammonium
Beyond the preview
Go deeper on [11C]-dimethyldiphenylammonium trifluoromethanesulfonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]-dimethyldiphenylammonium trifluoromethanesulfonate.